Abstract

Aurantii Fructus (AF) is one of the most well-known traditional herbal medicines frequently used for the treatment of cardiovascular symptoms in Korea. The anti-ischemic effects of AF on ischemia-induced isolated rat heart were investigated through analyses of changes in perfusion pressure, aortic flow, coronary flow, and cardiac output. The subjects in this study were divided into two groups: an ischemia-induced group without any treatment, and an ischemia-induced group with AF treatment. There were no significant differences in perfusion pressure, aortic flow, coronary flow, and cardiac output between them before ischemia was induced. The supply of oxygen and buffer was stopped for 10 min to induce ischemia in isolated rat hearts, and AF was administered during ischemia induction. AF treatment significantly prevented decreases in perfusion pressure, aortic flow, coronary flow, and cardiac output under ischemic conditions (p < 0.01). These results suggest that AF has distinct anti-ischemic effects through recovery of contractile dysfunction in ischemic heart. © 2007.

Author keywords

Anti-ischemia effect; Aurantii Fructus; Traditional herbal medicine

Indexed keywords

EMTREE drug terms: Aurantii fructus extract; herbaceous agent; plant extract; unclassified drug

EMTREE medical terms: animal experiment; animal model; animal tissue; aorta flow; article; controlled study; coronary artery blood flow; dose response; drug effect; heart muscle ischemia; heart output; heart protection; isolated heart; male; nonhuman; oxygen supply; rat; reperfusion injury

MeSH: Animals; Blood Flow Velocity; Blood Pressure; Cardiac Output; Citrus; Coronary Circulation; Dose-Response Relationship, Drug; Fruit; Heart Rate; Korea; Male; Medicine, Oriental Traditional; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Plant Extracts; Rats; Rats, Sprague-Dawley
Medline is the source for the MeSH terms of this document.

Species Index: Rattus

Chemicals and CAS Registry Numbers: Plant Extracts

Manufacturers:Drug manufacturer: sunten pharmaceutical, Taiwan.